Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men

BJU International

Volumn 101, Issue 3, 2008, Pages 313-318

  Parsons, J Kellogg ^a,b   Bergstrom, Jaclyn ^a   Barrett Connor, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benign prostatic hyperplasia; Cholesterol; Dyslipidaemia; Lower urinary tract symptoms; Risk factor; Triglyceride

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 37849030164     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07332.x     Document Type: Article

References (31)

1. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005 173 : 1256 61
2. Parsons JK, Carter HB, Partin AW et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006 91 : 2562 8
3. Giovannucci E, Rimm EB, Chute CG et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994 140 : 989 1002
4. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004 159 : 390 7
5. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005 96 : 88 92
6. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002 168 : 599 604
7. Kristal AR, Arnold KB, Schenk JM et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007 177 : 1395 400
8. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006 68 : 1198 205
9. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005 29 : 310 6
10. Joseph MA, Harlow SD, Wei JT et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003 157 : 906 14
11. Mitropoulos D, Ploumidou K. Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl 2003 2 : 20
12. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998 1 : 157 62
13. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006 370 : 89 93
14. Zucchetto A, Tavani A, Dal Maso L et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes (Lond) 2005 29 : 798 803
15. Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C. Serum lipid levels in benign prostatic hyperplasia. World J Urol 2006 24 : 210 3
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502
17. Kang D, Andriole GL, Van De Vooren RC et al. Risk behaviours and benign prostatic hyperplasia. BJU Int 2004 93 : 1241 5
18. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001 54 : 935 44
19. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985 121 : 78 90
20. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003 108 : 1541 5
21. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996 7 : 167 71
22. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005 150 : 859 70
23. Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 1982 115 : 657 63
24. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Impact of evidence-based 'clinical judgment' on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. The National Health Nutrition Examination Survey. Arch Intern Med 2000 160 : 1361 9
25. Gong Z, Neuhouser ML, Goodman PJ et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006 15 : 1977 83
26. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989 129 : 511 7
27. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007 178 : 395 401
28. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995 26 : 40 9
29. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 1997 82 : 1434 9
30. Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 2007 52 : 503 9
31. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003 5 (Suppl. 1 S19 27